Tag

Tirzepatide

All articles tagged with #tirzepatide

health2 days ago•4 min saved

Microdosing GLP-1 Weight Drugs: Small Wins, Uncertain Safety, Limited Evidence

A new observational study suggests that microdosing Wegovy (semaglutide) and Zepbound (tirzepatide) can lead to some weight loss, but far less than full-dose regimens and with different side effects; causation isn’t established. Over a year, low-dose tirzepatide users lost about 5.5% of body weight and low-dose semaglutide users about 2.2%, versus 20.2% and 13.7% in higher-dose trials. Side effects varied by drug and dose, with kidney-related issues and GI symptoms more common for tirzepatide, and ear inflammation, sweating, and ankle swelling more common for semaglutide. The study is observational and relies on electronic health records and AI-curated notes, so it cannot prove benefits or harms. Medical guidance emphasizes that weight loss at low doses is limited and decisions should be made with a healthcare provider; drugmakers continue to recommend gradual dose escalation to maintenance doses.

via USA Today|

#glp-1 #health #microdosing

health4 days ago•11 min saved

Weight-Loss GLP-1 Use Under Scrutiny as Misuse Risks Surface

An editorial warns that inappropriate use of GLP-1–based obesity drugs—often for cosmetic aims or through illicit channels—may cause serious health outcomes, including ketosis/ketoacidosis in young Japanese patients. It calls for shifting from simply discouraging off-label use to promoting 'appropriate weight reduction' via medically supervised treatment, adequate nutrition, and stronger regulatory safeguards, noting differing Japan reimbursement rules for GLP-1 medications.

via News-Medical|

#glp-1 #health #ketoacidosis

health4 days ago•0 min saved

FDA expands Mounjaro use to reduce heart risk in high‑risk diabetics

The FDA broadened Mounjaro’s use to lower major cardiovascular events in high‑risk adults with type 2 diabetes, with Lilly citing an additional 8% reduction versus Trulicity; the same drug is sold as Zepbound for weight loss, and Lilly is pursuing newer hormone‑targeting therapies.

via Action News 5|

#cardiovascular-outcomes #fda-approval #health

health5 days ago•2 min saved

Lilly’s Mounjaro Approved to Cut Heart-Risk in High-Risk Type 2 Diabetes

The FDA approved Eli Lilly’s diabetes drug Mounjaro (tirzepatide) to reduce the risk of heart attack or stroke in high‑risk adults with Type 2 diabetes, based on a trial showing an 8% lower rate of cardiovascular death, heart attack or stroke compared with Trulicity; Mounjaro is also marketed for weight loss as Zepbound. The piece highlights the growing GLP‑1 drug pipeline, including next‑generation therapies like retatrutide, and notes payer coverage trends that favor use for diabetes or cardiovascular risk reduction over obesity treatment.

via USA Today|

#cardiovascular-risk #glp-1 #health

health16 days ago•6 min saved

Tirzepatide Might Trigger More Hair Loss Than Semaglutide, Early Study Suggests

A preprint study comparing tirzepatide (Zepbound/Mounjaro) with semaglutide (Ozempic/Wegovy) in 8,985 women found higher incident alopecia with tirzepatide (5.44% vs 3.63%). At six months, 1.55% vs 1.24%; at twelve months, 4.20% vs 2.88%. After adjusting for weight loss, hair loss remained more common with tirzepatide (4.24% vs 3.33%), suggesting weight loss alone doesn’t explain the difference. The study is observational and not yet peer‑reviewed. Experts note GLP-1 meds can cause temporary shedding, and persistent patches should be evaluated by a dermatologist; patients should not stop their medication without physician guidance. The differing receptor targets (GIP/GLP-1 for tirzepatide vs GLP-1 alone for semaglutide) may influence the hair follicle environment, but mechanisms are not yet clear.

via Women's Health|

#alopecia #glp-1 #hair-loss

health22 days ago•48 min saved

19-Year-Old Student Dies After Using Common GLP-1 Weight-Loss Drug

A 19-year-old law student from Corona, California, died in a London dorm after taking tirzepatide, a widely prescribed GLP-1/GIP weight‑loss drug sold as Mounjaro and Zepbound. An inquest found her death was due to cardiac arrhythmia, with doctors noting a congenital heart condition (myocardial bridging) that may have contributed; vomiting could have triggered electrolyte imbalances leading to the arrhythmia. Nasr had been prescribed Zepbound by a U.S. doctor and was not obese, highlighting potential risks associated with GLP-1 therapies.

via Yahoo|

#cardiac-arrhythmia #glp-1-drugs #health

health23 days ago•7 min saved

College Student Dies After Using tirzepatide Weight-Loss Drug

A 19-year-old California college student died in her London dorm after taking tirzepatide, a GLP-1/GIP receptor agonist marketed for weight loss as Mounjaro and Zepbound; the incident comes amid rising use of GLP-1 weight-loss meds in the U.S. (about 15% have tried such medications) and ongoing safety discussions.

via The Daily Beast|

#collegestudentdeath #drugsafety #glp-1

health23 days ago•4 min saved

Mounjaro linked to lower heart attack risk in diabetics with heart disease

An observational study of about 53,000 people with type 2 diabetes and established heart disease found tirzepatide (Mounjaro) was associated with a 33% lower risk of major cardiovascular events, including heart attack, over roughly one year compared with sitagliptin; 2.9% vs 4.4% event rates, roughly one event prevented per 70 new tirzepatide users. The findings add to evidence GLP-1 meds may support heart health, but the study’s observational design and short follow-up limit conclusions, and tirzepatide is not FDA-approved for cardiac risk reduction.

via Healthline|

#glp-1 #health #heart-attack

health24 days ago•4 min saved

Coroner Cites Tirzepatide-Induced Electrolyte Imbalance in Student's Death

British coroner Graeme Irvine linked 19-year-old Josephine Nasr’s death in London to a cardiac arrhythmia associated with congenital heart disease and electrolyte imbalance caused by tirzepatide, a weight-loss/diabetes drug she had been prescribed in California. The inquest noted nausea from tirzepatide can trigger hypoglycemia and electrolyte disturbances that provoke dangerous arrhythmias, and the autopsy found a congenital heart condition; tirzepatide is not approved for under-18s and is associated with serious GI side effects.

via Where Is The Buzz|

#cardiac-arrhythmia #coroner-inquest #electrolyte-imbalance

health25 days ago•48 min saved

UK Coroner Ties Tirzepatide to Death of California Law Student

A British coroner ruled that tirzepatide contributed to the death of Josephine Nasr, a 19-year-old American law student at the University of East London, finding that a cardiac arrhythmia linked to a congenital heart condition and electrolyte imbalance from tirzepatide-induced hypoglycemia led to her death; an empty tirzepatide vial was found near her body, and Nasr had experienced nausea before she died. Eli Lilly warns the drug is not approved for cosmetic weight loss or for under-18 patients.

via Yahoo|

#cardiac-arrhythmia #coroner #electrolyte-imbalance

world26 days ago•24 min saved

Coroner links California student’s London death to Tirzepatide weight-loss drug

A 19-year-old California law student, Josephine Nasr, studying at the University of East London, was found dead in her dorm in September 2025. An inquest concluded the death was a cardiac arrhythmia caused by an electrolyte imbalance from hypoglycemia, triggered by Tirzepatide (Mounjaro/Zepbound), a prescribed weight‑loss drug; autopsy noted a congenital heart condition (myocardial bridging) that may have contributed, and an empty Tirzepatide vial was found at the scene.

via New York Post|

#arrhythmia #california #inquest

health29 days ago•13 min saved

UK Records Near-200 Deaths Linked to GLP-1 Weight-Loss Drugs, Regulator Cautions on Causation

UK MHRA Yellow Card data show roughly 200 deaths linked to GLP-1 obesity drugs (about 59 with semaglutide Ozempic/Wegovy, 120 with tirzepatide Mounjaro, 37 with liraglutide Saxenda) and over 150,000 adverse reactions. The regulator notes that reportings do not prove causation and many deaths may be due to underlying illnesses, while emphasizing GLP-1 medicines are safe for the majority of users; examples in investigations include deaths of Caroline Savage and Paula Owen.

via The Times of India|

#adverse-reactions #glp-1-weight-loss-drugs #health

health1 month ago•3 min saved

Women shed more weight than men on GLP-1 drugs like Mounjaro, study finds

A study in Obesity reports that overweight or obese women on tirzepatide (Mounjaro) lost about 15% of body weight after 15 months, compared with ~11% for men. While younger participants (<45) tended to lose more, age wasn’t the strongest predictor. Greater weight loss occurred among those without Type 2 diabetes, who hadn’t used weight‑loss meds before, and at higher doses. Possible explanations include slower drug clearance in women and estrogen’s effects; broader meta-analyses also show women often lose more weight on GLP-1 therapies.

via New York Post|

#glp-1 #health #study

health1 month ago•9 min saved

GLP-1 Weight Drugs May Dampen Binge Eating Symptoms, Review Finds

A meta-analysis of 25 RCTs (n=8,069) finds GLP-1 receptor agonists used for weight loss—such as semaglutide, tirzepatide, and liraglutide—also reduce binge eating, loss-of-control eating, and emotional eating beyond weight loss, while dietary restraint tends to rise. Researchers caution that most trials had bias and limited BED-diagnosed samples, and emphasize integrating medication with psychological therapy and social support, plus addressing public-access barriers. More independently funded, long-term studies are needed to confirm clinical utility.

via Neuroscience News|

#binge-eating-disorder #glp-1-receptor-agonists #health

health1 month ago•17 min saved

High-Dose GLP-1 Drugs May Dim Joy, Doctors Warn

Doctors report three cases of anhedonia (loss of pleasure) in people taking the obese‑treating GLP-1 drug tirzepatide at very high doses (up to 15 mg/week). In all cases, symptoms eased after reducing the dose (and in one case adding an antidepressant), suggesting the effect is dose-related and manageable. The side effect is linked to GLP-1s’ influence on brain reward regions like the ventral tegmental area, though GLP-1 therapies remain associated with reduced depression symptoms overall. Clinicians emphasize monitoring motivation and pleasure during treatment, especially at higher doses, and note that this should not deter indicated use for obesity or type 2 diabetes while remaining vigilant and adjusting dosing as needed.

via Gizmodo|

#adverse-effects #anhedonia #glp-1s